At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
RedDress Wound Care System (RD1)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.
In Brief
A Phase 2 clinical trial evaluating RedDress Wound Care System (RD1) for Neuropathic Diabetic Ulcer - Foot. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the safety of the RedDress Wound Care System (RD1) in patients Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Diabetic Ulcer - Foot
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartMay 2014
Primary CompletionAug 2016
Study CompletionMar 2017
TodayJul 2026
First PostedJul 19, 2011
Enrollment StartMay 1, 2014
Primary CompletionAug 1, 2016
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.0 years ago
Interventions
RedDress Wound Care System (RD1)device
Weekly application. A blood based wound care treatment